Milestone Pharmaceuticals is trading 14.89% down now at $1.08 after its August 12, 2026 second-quarter report missed Wall Street expectations.
- Product revenue reached $559,000, below analysts’ $800,000 estimate; adjusted loss was $0.21 per share versus an expected $0.19 loss.
- Coverage expanded beyond 50% of commercially insured U.S. lives, with cash runway into H2 2027, but launch revenue remains weak.
- Shares were reported down 12.60% following the announcement.